Phase 2 N=20 Study of Tocilizumab to Treat Polymyalgia Rheumatica
Polymyalgia Rheumatica (PMR)
Primary: Proportion of Patients in Disease Remission at Six Months From Trial Entry — 9; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=9 Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer
Estrogen Receptor-negative Breast Cancer · HER2-negative Breast Cancer · Progesterone Receptor-negative Breast Cancer
Primary: Count of Participants That Achieve Pathologic Complete Response (PCR) — 3; 3 Participants
Phase 2 N=40 Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers
Recurrent Melanoma · Stage III Melanoma · Stage IV Melanoma
Primary: MTD, Defined as One Dose Level Below the Dose That Induced DLT in at Least One Third of Patients at a Dose Level, Graded According to NCI CTCAE Version 3.0 (Phase I) — 2…
Phase 2 N=153 Study to Evaluate the Efficacy and Safety of PT20 in Subjects With Hyperphosphataemia and Dialysis Dependent Chronic Kidney Disease
Hyperphosphataemia
Primary: Change in Serum Phosphate Concentration From Baseline (Visit 7, Day 1) to Visit 11 (Day 29) — -0.4; -0.59; -1.29; -1.363 mg/dL — p=0.784
Phase 2 N=229 Study of FX006 in Patients With Osteoarthritis of the Knee
Osteoarthritis of the Knee
Primary: Change From Baseline to Week 8 in Weekly Mean of the Average Daily (24-hour) Pain Intensity Score for FX006 60 mg vs TCA IR 40 mg — -3.9; -3.4 units on a scale — p=0.1249
Phase 2 N=126 Trial of CPX-351 in Newly Diagnosed Elderly AML Patients
Acute Myeloid Leukemia
Primary: Number of Participants With Complete Remission — 41; 20 Participants
Phase 2 N=81 Study to Characterize the PK and Local Extent and Duration of Exposure From FX006 in Patients With OA of the Knee
Osteoarthritis of the Knee
Primary: Synovial Fluid Drug Concentrations (pg/mL) by Time Point Pooled Across FX006 Cohorts and TCA IR in Synovial Fluid — 1.0; 1.0; 231328.9; 3590.0 pg/mL
Phase 2 N=203 Edoxaban in Peripheral Arterial Disease
Peripheral Arterial Disease
Primary: Percentage of Participants With Clinically Relevant Bleeding During Treatment — 8; 11; 6; 6 percentage of participants
Phase 2 N=107 A Phase II Clinical Study of SB-480848 in Dyslipidemic Patients
Atherosclerosis
Primary: Change From Baseline to Week 4 in Plasma Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Activity — 0.961; 0.494; 0.404; 0.313 Log(millimole per milliliter per minute)…
Phase 2 N=50 Study to Characterize the Local Duration of Exposure From FX006 in Patients With Osteoarthritis of the Knee
Osteoarthritis of the Knee
Primary: Concentration of Triamcinolone Acetonide in Synovial Fluid — 477.5; 923.7; 250.1; NA pg/mL
Phase 2 N=52 Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
Previously Treated Myelodysplastic Syndrome · Recurrent Adult Acute Myeloid Leukemia
Primary: Most Efficacious and Tolerated Dosage of Decitabine (Period 1) — 0; 0; 0; 1 Incidents
Phase 2 N=27 Practice Effects and Amyloid Imaging Using 18F-PIB or Flutemetamol PET and FDG-PET
Alzheimer's Disease
Primary: Amyloid Deposition Obtained on a 18F-flutemetamol Brain Scan. — 1.65 ratio of flutemetamol absorbed — p=<0.05
Phase 2 N=64 Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer
Ovarian Carcinoma
Primary: Median Proportion Cells That Are Apoptotic in Epithelial Ovarian Tissue — .093; .115 proportion of total cells
Phase 2 N=17 MT2014-25: Haplo NK With SQ IL-15 in Adult Relapsed or Refractory AML Patients
Acute Myelogenous Leukemia
Primary: < 5% Marrow Blast, no Circulating Peripheral Blasts and Neutrophil Count of > 1 x 10^9/L — 5 Participants
Phase 2 N=176 Safety and Effectiveness of Low-Dose Methotrexate for Reducing Inflammation in HIV-Infected Adults on ARV Medications
HIV Infections
Primary: Number of Participants Who Reached at Least One Safety Milestone Over the Duration of Study Follow-up (36 Weeks) — 11; 5 Participants — p=0.0367